We Mean Business: Will revamped pharma policy address industry concerns?
Ahead of the crucial meeting by the group of ministers (GoM) and Finance Minister P Chidambaram on the method of arriving at the pricing for essential drugs, experts Kiran Mazumdar Shaw, chairman and managing director of Biocon, Mira Shiva from All India Drug Action Network (AIDAN), Kewal Handa, industry expert and former MD of Pfizer, and Abhaya Kumar, MD of Shasun Pharmaceuticals, discuss if the revamped pharmaceutical policy can address concerns of all stakeholders, the industry, the activists and the people at large.
